Myelofibrosis (MF) is a rare and chronic bone marrow disorder classified under the group of myeloproliferative neoplasms (MPNs). It is characterized by the replacement of bone marrow with fibrous (scar) tissue, leading to ineffective blood cell production, anemia, and enlargement of the spleen and liver.
<h3 dir="ltr">Epidemiology Segmentation</h3>
<ul>
<li dir="ltr" aria-level="1">
Total Prevalent Cases of Myelofibrosis&nbsp;
</li>
<li dir="ltr" aria-level="1">
Total Diagnosed Prevalent cases of Myelofibrosis&nbsp;
</li>
<li dir="ltr" aria-level="1">
Type-specific Prevalent Cases of Myelofibrosis
</li>
<li dir="ltr" aria-level="1">
Myelofibrosis Cases Based on Risk Stratification&nbsp;
</li>
<li dir="ltr" aria-level="1">
Age-specific Prevalent Cases of Myelofibrosis&nbsp;
</li>
<li dir="ltr" aria-level="1">
Myelofibrosis Cases Based on Molecular Alterations
</li>
<li dir="ltr" aria-level="1">
Transplant Eligible/Ineligible Cases of Myelofibrosis&nbsp;
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/myelofibrosis-mf-epidemiology-forecast">Myelofibrosis Epidemiology</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In 2024, the total prevalent cases of myelofibrosis across the 7MM were estimated at approximately 55,900, with numbers expected to rise throughout the study period (2020&ndash;2034).
</li>
<li dir="ltr" aria-level="1">
Within the EU4 and the UK, Germany reported the highest number of diagnosed prevalent myelofibrosis cases in 2024, followed by Spain, while the UK had the lowest number of cases.
</li>
<li dir="ltr" aria-level="1">
In the U.S., high-risk patients represented the largest proportion of myelofibrosis cases in 2024, based on risk classification (low, intermediate-1, intermediate-2, and high risk).
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/myelofibrosis-mf-market">Myelofibrosis Market</a></h3>
<ul>
<li dir="ltr" aria-level="1">
The total myelofibrosis market size in the 7MM was approximately USD 2.2 billion in 2024, with growth anticipated throughout the forecast period (2024&ndash;2034).
</li>
<li dir="ltr" aria-level="1">
The U.S. dominated the market in 2024, with a size of nearly USD 1.7 billion, surpassing the combined markets of the EU4, the UK, and Japan.
</li>
<li dir="ltr" aria-level="1">
Among available therapies, JAKAFI/JAKAVI (ruxolitinib) is projected to generate the highest revenue in the 7MM by 2034.
</li>
</ul>
<h3 dir="ltr">Myelofibrosis Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
Growing awareness and improved diagnostic tools are leading to higher identification of MF cases globally, expanding the patient population requiring treatment.
</li>
<li dir="ltr" aria-level="1">
The introduction and adoption of JAK inhibitors like ruxolitinib and fedratinib have significantly improved symptom management and quality of life, fueling market growth.
</li>
<li dir="ltr" aria-level="1">
Ongoing clinical trials and research into new agents, including combination therapies and next-generation JAK inhibitors, promise better outcomes and stimulate market expansion.
</li>
</ul>
<h3 dir="ltr">Myelofibrosis Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
Targeted therapies and advanced treatment options are often expensive, limiting access, especially in emerging markets and among underinsured populations.
</li>
<li dir="ltr" aria-level="1">
Allogeneic stem cell transplant remains the only curative treatment but is applicable to a small subset of patients due to age and comorbidities, restricting overall market potential.
</li>
<li dir="ltr" aria-level="1">
Adverse effects associated with current therapies and the development of resistance or loss of response over time can reduce patient adherence and limit long-term efficacy.
</li>
</ul>
<h3 dir="ltr">Myelofibrosis Key Players</h3>
<ul>
<li dir="ltr" aria-level="1">
Abbvie&nbsp;&nbsp;
</li>
<li dir="ltr" aria-level="1">
Morphosys&nbsp;&nbsp;
</li>
<li dir="ltr" aria-level="1">
Geron&nbsp;&nbsp;
</li>
<li dir="ltr" aria-level="1">
Bristol Myers Squibb&nbsp;&nbsp;
</li>
<li dir="ltr" aria-level="1">
Kartos Therapeutics&nbsp;&nbsp;
</li>
<li dir="ltr" aria-level="1">
Karyopharm Therapeutics&nbsp;&nbsp;
</li>
<li dir="ltr" aria-level="1">
Ns Pharma&nbsp;&nbsp;
</li>
<li dir="ltr" aria-level="1">
Galecto Biotech&nbsp;&nbsp;
</li>
<li dir="ltr" aria-level="1">
Actuate Therapeutics&nbsp;&nbsp;
</li>
<li dir="ltr" aria-level="1">
Merck&nbsp;&nbsp;
</li>
<li dir="ltr" aria-level="1">
Menarini Group&nbsp;&nbsp;
</li>
<li dir="ltr" aria-level="1">
Telios Pharma&nbsp;&nbsp;
</li>
<li dir="ltr" aria-level="1">
Disc Medicine&nbsp;&nbsp;
</li>
<li dir="ltr" aria-level="1">
Syntara&nbsp;&nbsp;
</li>
<li dir="ltr" aria-level="1">
Sumitomo Pharma&nbsp;&nbsp;
</li>
<li dir="ltr" aria-level="1">
Incyte&nbsp;
</li>
</ul>
And others.

Myelofibrosis Market Infographic

Myelofibrosis Market Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.